Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409107 · ClinicalTrials.gov registry record · Phase 3
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT03409107 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 614 participants.
The verdict
NCT03409107, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
Interventions
- DRUG Placebo
- DRUG Daprodustat (GSK1278863)
- DRUG Iron therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409107
The ClinicalTrials.gov registry entry for NCT03409107 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03409107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409107 about?
NCT03409107 is a clinical study titled "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)". The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
What is the current status of trial NCT03409107?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2018-03-05. Estimated completion is 2020-10-07.
What interventions are being tested in trial NCT03409107?
The interventions under investigation include: Placebo (DRUG), Daprodustat (GSK1278863) (DRUG), Iron therapy (DRUG).
Who is sponsoring clinical trial NCT03409107?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.